DTIL icon

Precision BioSciences

4.72 USD
+0.12
2.61%
At close Dec 20, 4:00 PM EST
After hours
4.70
-0.02
0.42%
1 day
2.61%
5 days
-11.28%
1 month
-34.26%
3 months
-50.88%
6 months
-51.69%
Year to date
-57.48%
1 year
-56.30%
5 years
-98.90%
10 years
-99.10%
 

About: Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Employees: 108

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

9% more funds holding

Funds holding: 47 [Q2] → 51 (+4) [Q3]

0.2% more ownership

Funds ownership: 45.77% [Q2] → 45.97% (+0.2%) [Q3]

3% less capital invested

Capital invested by funds: $30.9M [Q2] → $29.8M (-$1.07M) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for DTIL.

Financial journalist opinion

Neutral
Business Wire
3 days ago
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it has received Clinical Trial Application (CTA) approval in Hong Kong to study PBGENE-HBV in the ongoing ELIMINATE-B Phase I trial. PBGENE-HBV is Precision's lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by.
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
Neutral
Business Wire
1 month ago
Precision BioSciences to Participate in Upcoming November Investor Conferences
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. JonesTrading Virtual Genetic Medicine Day Date: Monday, November 25, 2024 Time: 11:00 AM ET Panel Title: Next Generation of Gene Editing; Going Beyond “Cas” Webcast Link: Regist.
Precision BioSciences to Participate in Upcoming November Investor Conferences
Neutral
Business Wire
1 month ago
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today will present preclinical data supporting the advancement of PBGENE-HBV into clinical development. The Company will also outline the design of its first-in-human study, ELIMINATE-B, in patients with chronic hepatitis B. Company management will present these upd.
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Negative
Zacks Investment Research
1 month ago
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $3 per share a year ago.
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Business Wire
1 month ago
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. “With the clearance of our first clinical trial application (CTA) for our lead program, PBGENE-HBV, we have arrived at the next phase of Precision's jou.
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Positive
Zacks Investment Research
1 month ago
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
Neutral
Business Wire
1 month ago
Precision BioSciences to Report Third Quarter Results on November 4, 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (D.
Precision BioSciences to Report Third Quarter Results on November 4, 2024
Neutral
Business Wire
1 month ago
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. – 8:30 a.m. PST prior to the American Association for the Study of Liver Diseases (AASLD) Meeting. The event will feature Key Opinion Leaders in the field of Hepat.
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Neutral
Business Wire
1 month ago
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress being held October 22-25, 2024, in Rome, Italy. The poster highlighted preclinical data demonstrating the ability of ARCUS to achieve high-efficienc.
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Neutral
Business Wire
1 month ago
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it has received Clinical Trial Application (CTA) approval in Moldova for its lead candidate, PBGENE-HBV. PBGENE-HBV is Precision's wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key sour.
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
Charts implemented using Lightweight Charts™